Botanix Pharmaceuticals Limited · ASX:BOT
Botanix Pharmaceuticals — Euroz Hartleys Healthcare Forum 2024
12 slides from Botanix Pharmaceuticals's conference presentation, Feb 6, 2024
Slide 1: Euroz Hartleys Healthcare Forum Presentation
6 February 2024 Euroz Hartleys Healthcare Forum Presentation Key highlights • Botanix CEO Dr Howie McKibbon is presenting at the Euroz Hartleys Healthcare Forum being held today in Perth, Western Australia • The Conference attracts attendees from leading institutional investors around Australia and
Slide 2: Cautionary Note on Forward-Looking Statements
For more information, please contact: General enquiries Investor enquiries Media enquiries Corporate Communications Hannah Howlett Haley Chartres Botanix Pharmaceuticals WE Communications H^CK P: +61 8 6555 2945 P: +61 450 648 064 P: +61 423 139 163 investors@botanixpharma.com hhowlett@we-worldwide.
Slide 3: Botanix Overview
For personal use only Botanix Overview February 2024 www.botanixpharma.com
Slide 4: Important Notice & Disclaimer
Important Notice & Disclaimer 1. Summary information This presentation has been prepared by Botanix Pharmaceuticals Ltd (“Botanix”) and contains summary information about Botanix and the business conducted by it which is current as at the date of this presentation (“Presentation”) (unless otherwise
Slide 5: Botanix – Accelerating towards commercialization of Sofdra
Botanix – Accelerating towards commercialization of Sofdra™️ 1 For personal use only New treatments for underserved common skin diseases, with a first focus DERMATOLOGY FOCUS on excessive sweating (“primary axillary hyperhidrosis”) Targeting key indications with topical (gel) treatments that are saf
Slide 6: World class board and management team
World class board and management team Developed, secured approval for and commercialised over 30 successful dermatology products For personal use only VINCE IPPOLITO HOWIE MCKIBBON DR PATRICIA WALKER MATT CALLAHAN Executive Chairman Chief Executive Officer Chief Medical Adviser Board Executive Direc
Slide 7: Large addressable market of ~10M patients actively seeking solutions
Large addressable market of ~10M patients actively seeking solutions For personal use only US Hyperhidrosis Population ~336M Hyperhidrosis Patients ~16.1M Potential to diagnose and treat Axillary Hyperhidrosis from home with telemedicine ~10M Patients Patients already in dermatologist’s Patients See
Slide 8: Significant opportunity for a new topical agent
Significant opportunity for a new topical agent For personal use only OLDER PRESCRIPTION ANTIPERSPIRANTS NEW CHEMICAL ENTITIES PRODUCTS INVASIVE PROCEDURES SURGERY OTC ALUMINUM CHLORIDE BOTOX INJECTION CUTTING NERVES REFORMULATED ORAL DRUG INTO A SOLUTION CLINICAL STRENGTH SOFDRA HEAT ENERGY DEVICE
Slide 9: Sofdra launch strategy
Sofdra™️ launch strategy For personal use only Rapidly establish Sofdra as a first-line topical treatment of primary axillary hyperhidrosis, in patients 9 years of age and older Drive dermatology adoption through comprehensive engagement around a compelling clinical story Engage and motivate patient
Slide 10: Proactive, pre-approval engagement with plans >200K lives
Proactive, pre-approval engagement with plans >200K lives For personal use only Rx Con PBM Account Lives Rnk Clin Pres CVS CVS Caremark - Advanced Control, Performance Standard Control, Value 1,845,000 1 Yes ❖ Completed payor profiles and engagement EXPRESS Express Scripts - High Performance, Basic
Slide 11: Focused pre-launch period ahead
Focused pre-launch period ahead ❖ FDA approval targeted for late June 2024 For personal use only ❖ Only remaining issue to be addressed for FDA approval relates to patient Instructions for Use – no efficacy, safety or manufacturing issues ❖ Commercial preparation accelerating, given de-risking of FD
Slide 12: Botanix Overview
For personal use only Botanix Overview February 2024 www.botanixpharma.com
Botanix Pharmaceuticals — Euroz Hartleys Healthcare Forum 2024 on 6ix